Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
61.45
+0.48 (0.79%)
At close: Apr 24, 2026, 4:00 PM EDT
61.00
-0.45 (-0.73%)
After-hours: Apr 24, 2026, 5:17 PM EDT
Tarsus Pharmaceuticals Employees
Tarsus Pharmaceuticals had 370 employees as of December 31, 2025. The number of employees increased by 47 or 14.55% compared to the previous year.
Employees
370
Change (1Y)
47
Growth (1Y)
14.55%
Revenue / Employee
$1,219,892
Profits / Employee
-$179,508
Market Cap
2.62B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 370 | 47 | 14.55% |
| Dec 31, 2024 | 323 | 79 | 32.38% |
| Dec 31, 2023 | 244 | 157 | 180.46% |
| Dec 31, 2022 | 87 | 41 | 89.13% |
| Dec 31, 2021 | 46 | 26 | 130.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| ADMA Biologics | 647 |
| Beam Therapeutics | 511 |
| Vera Therapeutics | 249 |
| Celldex Therapeutics | 198 |
| Soleno Therapeutics | 182 |
| Immunome | 177 |
| Disc Medicine | 155 |
TARS News
- 25 days ago - Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease - GlobeNewsWire
- 4 weeks ago - TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus - GlobeNewsWire
- 6 weeks ago - Tarsus Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 7 weeks ago - Tarsus Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Tarsus to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Tarsus Pharmaceuticals Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors - GlobeNewsWire
- 2 months ago - Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026 - GlobeNewsWire